New hope for painful skin condition: experimental drug aims to reduce flare-ups
NCT ID NCT07244510
First seen Dec 08, 2025 · Last updated Apr 29, 2026 · Updated 18 times
Summary
This study tests an experimental drug, SCT650C, in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants receive either the drug or a placebo to see if it reduces skin bumps and inflammation by at least 75% after 16 weeks. The goal is to find a safer, more effective treatment option for HS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA \(HS\) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ondokuz Mayis University Medical Faculty
RECRUITINGSamsun, Turkey, 55200, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.